Infant Bacterial Therapeutics AB (publ) (IBT-B) — Cash Flow-to-Debt Ratio
Infant Bacterial Therapeutics AB (publ) (IBT-B) has a Cash Flow-to-Debt Ratio of -0.97x as of September 2025, meaning its operating cash flow of Skr-52.25 Million could theoretically repay -1% of its total liabilities (Skr53.87 Million) in one year. See how liquid is Infant Bacterial Therapeutics AB (publ)'s working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Infant Bacterial Therapeutics AB (publ) Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Infant Bacterial Therapeutics AB (publ) across 11 annual periods. Also explore Infant Bacterial Therapeutics AB (publ) (IBT-B) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Infant Bacterial Therapeutics AB (publ) (2014–2024)
Year-by-year debt coverage analysis for Infant Bacterial Therapeutics AB (publ). For market capitalisation and broader financial context, see Infant Bacterial Therapeutics AB (publ) (IBT-B) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.63x | Skr-113.13 Million | Skr69.30 Million | ▲ +25.5% |
| 2023 | -2.19x | Skr-101.22 Million | Skr46.18 Million | ▲ +54.2% |
| 2022 | -4.79x | Skr-85.80 Million | Skr17.91 Million | ▼ -13.9% |
| 2021 | -4.21x | Skr-55.62 Million | Skr13.22 Million | ▲ +26.8% |
| 2020 | -5.74x | Skr-58.39 Million | Skr10.16 Million | ▲ +11.8% |
| 2019 | -6.51x | Skr-51.30 Million | Skr7.88 Million | ▲ +8.6% |
| 2018 | -7.12x | Skr-47.41 Million | Skr6.65 Million | ▼ -36.4% |
| 2017 | -5.23x | Skr-34.76 Million | Skr6.65 Million | ▲ +35.8% |
| 2016 | -8.14x | Skr-39.75 Million | Skr4.88 Million | ▼ -269.8% |
| 2015 | -2.20x | Skr-17.02 Million | Skr7.73 Million | ▼ -104.6% |
| 2014 | -1.08x | Skr-3.77 Million | Skr3.51 Million | — |